Additionally, Tremblay et al. (2014) and Zobel et al. (2021) found that GLP-1RAs lowered the plasma levels of IL-18 and IL-1β in individuals with T2D, which suggests that GLP-1RAs could prevent the inflammasome from cleaving and releasing pro-inflammatory cytokines into the bloodstream. This evidence concerns the gene IL18 and type 2 diabetes mellitus.